For many patients, the question is straightforward: can NHS doctors prescribe cannabis when standard treatment has failed? The legal answer is yes, but the practical answer is far more restricted. Cannabis-based medicines have been lawful on prescription in the UK since November 2018, yet NHS access remains limited to a small number of licensed medicines and tightly defined clinical circumstances.
That gap matters. Patients may hear that medical cannabis is legal, then discover that their GP cannot simply issue a prescription for cannabis flower, oil or a vape cartridge. The route through the NHS is specialist-led, evidence-led and, in most cases, difficult to access.
Can NHS doctors prescribe cannabis?
NHS doctors can prescribe cannabis-based products for medicinal use, often shortened to CBPMs. However, the prescriber must normally be a doctor listed on the General Medical Council Specialist Register, and the decision must sit within their area of specialist practice.
This means a GP cannot initiate a prescription for an unlicensed medical cannabis product. A GP may be involved in a patient’s wider care and, in limited cases, may prescribe under a formal shared-care arrangement put in place by a specialist. But that is different from independently assessing someone for medical cannabis and starting treatment.
The law does not create an automatic right to treatment. As with any NHS medicine, a clinician must decide that a product is clinically appropriate, safe for the individual, and supported by the available evidence. Local NHS commissioning arrangements also affect whether a treatment is funded.
What can actually be prescribed on the NHS?
The NHS does not prescribe recreational cannabis, and it does not dispense cannabis obtained from an unregulated source. The products used in routine NHS care are generally licensed medicines with specific indications, doses and safety information.
Three cannabis-derived or cannabinoid medicines are the best-known examples. Sativex, a mouth spray containing THC and CBD, is licensed for moderate to severe spasticity in multiple sclerosis. It may be considered when other treatments have not worked, but NHS availability varies across the UK and local approval processes can be restrictive.
Epidyolex contains purified cannabidiol, or CBD. It is used alongside other anti-seizure medicines for certain rare, severe forms of epilepsy, including Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex. This is a pharmaceutical medicine, not the same thing as a CBD oil sold on the high street or online.
Nabilone is a synthetic cannabinoid. It can be prescribed for nausea and vomiting caused by chemotherapy when other anti-sickness medicines have not provided enough relief. It is not cannabis flower and does not contain plant-derived THC in the same way as many medical cannabis products.
These medicines account for the clearest NHS prescribing routes. They are not a general pathway for anxiety, insomnia, chronic pain, PTSD, ADHD or other conditions often discussed in the private medical cannabis market.
Why is NHS medical cannabis access so limited?
The central issue is evidence. NHS prescribing decisions are guided by clinical trials, regulatory approvals, safety data and cost-effectiveness assessments. For many uses of unlicensed cannabis-based products, particularly chronic pain, the evidence base has not yet met the standard needed for routine commissioning.
NICE guidance has reflected that caution. It supports the use of certain licensed products for specific conditions, while making more limited recommendations for unlicensed CBPMs. For chronic pain, for example, NICE has generally advised against offering cannabis-based medicines outside a clinical trial because of uncertain long-term benefit, potential harms and limitations in the evidence.
This can feel disconnected from patient experience. Some people report meaningful improvements in pain, sleep, muscle spasms or quality of life after private treatment. Individual benefit, however, is not the same as the level of evidence the NHS needs before funding a medicine at population scale. Both can be true at once.
There are also safety considerations. THC-containing medicines can affect concentration, coordination, mood and perception. They may interact with other medicines and can be unsuitable for some people, including those with a personal or family history of psychosis. Clinicians also need to consider pregnancy, cardiovascular risk, dependence, safeguarding and the patient’s ability to drive safely.
What about unlicensed medical cannabis products?
Specialists can legally prescribe an unlicensed CBPM where they consider it appropriate. These products can include oils, capsules, oral preparations and cannabis flower intended for use with a medical vaporiser. This is often what people mean when they refer to a “medical cannabis prescription”.
In theory, this route is available through the NHS. In practice, it is rarely used. NHS specialists may be reluctant to prescribe without stronger evidence, an established local policy, funding approval or support from their trust. Some clinicians also have limited experience of prescribing these products, which is understandable given the relative newness of the legal framework.
Most prescriptions for unlicensed medical cannabis in the UK are therefore issued by private clinics. Patients typically pay for the initial consultation, follow-up appointments, medication and, where relevant, a repeat prescription fee. Costs can be substantial and ongoing. A private prescription is legal when issued by an appropriate specialist, but it does not mean the medicine is available free of charge or transferable to NHS care.
Private care also varies in quality. Patients should expect a proper medical assessment, discussion of alternatives, screening for risks and clear advice on side effects, driving and treatment review. A clinic that presents cannabis as risk-free, guarantees eligibility or encourages self-diagnosis should raise concerns.
Can your GP refer you for medical cannabis?
A GP can refer a patient to an NHS specialist where there is a relevant clinical need, but a referral does not guarantee an assessment specifically for medical cannabis. The specialist service will usually focus first on diagnosing the condition and optimising established treatments.
If a person has exhausted conventional options, it is reasonable to ask their GP or consultant whether a licensed cannabinoid medicine is relevant to their diagnosis. For conditions outside the recognised NHS indications, patients can ask whether an unlicensed CBPM is clinically appropriate, while recognising that the answer may be no.
Patients considering a private clinic do not usually need an NHS referral, although clinics commonly request medical records or a summary of care. This is not bureaucracy for its own sake. A prescriber needs to understand current medicines, previous treatment, relevant diagnoses and potential contraindications before making a decision.
A prescription does not change every legal rule
A valid prescription provides a lawful basis to possess the prescribed medicine when it is used as directed. It does not give someone permission to grow cannabis at home, share it with another person, take it abroad without checking destination rules, or consume it wherever they choose.
Driving is one area where patients need particular care. Certain controlled drugs, including THC, have specified limits in road traffic law. A medical defence may be available where the medicine was prescribed, taken in accordance with instructions and the driver was not impaired. But that is not a blanket exemption. Police can still investigate, and impairment remains an offence regardless of a prescription.
Employers, landlords, schools, hospitals and venues may also have their own rules around smoking, vaping, storage and medicine use. Medical cannabis flower is generally intended to be vaporised, not smoked. Patients should keep it in its original labelled packaging and carry evidence of their prescription when travelling with it in the UK.
What patients should do next
The most useful first step is to separate the legal question from the treatment question. Legal status tells you that a specialist may prescribe a cannabis-based medicine. It does not establish that it is suitable, funded or likely to be available through the NHS for your condition.
Speak openly with the clinician managing the condition, particularly about what has already been tried, what has not worked and what outcomes matter most to you. Ask about licensed options first, and be realistic about the distinction between NHS treatment and private prescribing. Good medical cannabis care is not about finding the fastest route to a prescription. It is about making a properly informed decision that protects your health, legal position and finances.
